Helicobacter pylori and Risk of Nonalcoholic Fatty Liver Disease

Journal of Clinical Gastroenterology

Volumn 52, Issue 5, 2018, Pages 386-391

  Wijarnpreecha, Karn ^a   Thongprayoon, Charat ^a   Panjawatanan, Panadeekarn ^f   Manatsathit, Wuttiporn ^b   Jaruvongvanich, Veeravich ^c   Ungprasert, Patompong ^d,e  

^a BASSETT MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d MAYO CLINIC   (United States)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

helicobacter; Helicobacter pylori; insulin resistance; meta analysis; nonalcoholic fatty liver; nonalcoholic steatohepatitis

Indexed keywords

ARTICLE; DISEASE ASSOCIATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; COMPLICATION; INFLAMMATION; INSULIN RESISTANCE; ISOLATION AND PURIFICATION; META ANALYSIS; MICROBIOLOGY; RISK FACTOR;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 85009732774     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000784     Document Type: Article

References (37)

1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-2273
2. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923
3. Wijarnpreecha K, Thongprayoon C, Edmonds PJ, et al. Associations of sugar-and artificially sweetened soda with nonalcoholic fatty liver disease: a systematic review and metaanalysis. QJM. 2015;109:461-466
4. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Short sleep duration and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:1802-1807
5. Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787-1794
6. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887
7. Nieuwdorp M, Gilijamse PW, Pai N, et al. Role of the microbiome in energy regulation and metabolism. Gastroenterology. 2014;146:1525-1533
8. Buzas GM. Metabolic consequences of Helicobacter pylori infection and eradication. World J Gastroenterol. 2014;20: 5226-5234
9. Li M, Shen Z, Li YM. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol. 2013;19:7024-7031
10. Okushin K, Takahashi Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale crosssectional study in Japan. BMC Gastroenterol. 2015;15:25
11. Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62:121-126
12. Shen ZQY, Lu Y, Yu C, et al. Association between Helicobacter pylori infection diagnosed by serological status and nonalcoholic fatty liver disease: a cross-sectional study. United Eur Gastroenterol J. 2013;1:A99
13. Baeg MK, Yoon SK, Ko SH, et al. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22:2592-2600
14. Kang SKD, Kim J, Cho S. Association between Helicobacter pylori and nonalcoholic fatty liver disease in the general population. Helicobacter. 2013;18(suppl 1):114
15. Tang DM, Chou JY, Ho N, et al. Helicobacter pylori infection is strongly associated with metabolic syndrome, and almost meets significance with non-alcoholic fatty liver disease, in a United States Hispanic population. Gastroenterology. 2016;4: S299
16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605
17. Herzog R, Alvarez-Pasquin MJ, Diaz C, et al. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes A systematic review. BMC Public Health. 2013;13:154
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188
19. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560
20. Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet. 1991;337:867-872
21. Eshraghian A, Eshraghian H, Ranjbar Omrani G. Insulin resistance and metabolic syndrome: is Helicobacter pylori criminal Minerva gastroenterologica e dietologica [Minerva Gastroenterol Dietol]. 2011;57:379-385
22. Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PloS one. 2008;3:e1765
23. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. New Engl J Med. 1991;325: 938-948
24. Manolakis AC, Tiaka EK, Kapsoritakis AN, et al. Increased fetuin A levels in Helicobacter pylori infection: a missing link between H. pylori and insulin resistance Diabetologia. 2011;54:472-474
25. Ou HY, Yang YC, Wu HT, et al. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab. 2012;97:4717-4723
26. Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18:1279-1285
27. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin Hepatology. 2004;40: 46-54
28. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr. 2011;53:131-140
29. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011;12: 695-708
30. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59-69
31. Li HJ, Li CP, Zhang C, et al. Association of adiponectin gene polymorphisms and nonalcoholic fatty liver disease. Int J Clin Exp Med. 2015;8:16676-16681
32. Zhang C, Guo L, Qin Y, et al. Correlation between Helicobacter pylori infection and polymorphism of adiponectin gene promoter-11391 G/A, superoxide dismutase gene innonalcoholic fatty liver disease. J Central South University Med Sci. 2016;41:359-366
33. Zhou YJ, Zhang ZS, Nie YQ, et al. Association of adiponectin gene variation with progression of nonalcoholic fatty liver disease: a 4-year follow-up survey. J Dig Dis. 2015;16:601-609
34. Fukuda YBH, Okui M, Tamura K, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion. 2001;63(suppl 1):93-96
35. Huang Y, Tian XF, Fan XG, et al. The pathological effect of Helicobacter pylori infection on liver tissues in mice. Clin Microbiol Infect. 2009;15:843-849
36. Sumida Y, Kanemasa K, Imai S, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J Gastroenterol. 2015;50:996-1004
37. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781.